BSA-Deruxtecan Conjugate

Deruxtecan is an exatecan (Exa) derivative appended with a cleavable peptide linker. It is a very potent inhibitor of topoisomerase I and an anticancer agent. Deruxtecan is used to prepare antibody-drug conjugates (ADCs), such as trastuzumab Deruxtecan (T-DXd, also known as Enhertu®, Daiichi Sankyo), targeting HER2. Deruxtecan is approved in HER2-expressing breast (BC) and gastric (GC) cancers. This BSA-Deruxtecan conjugate is designed with the same linker chemistry as PDCs prepared using our Protein Deruxtecan Conjugation Kit (Cat#: CM11432). The BSA-Deruxtecan conjugate is synthesized and has an average loading of 3 to 5 Deruxtecan molecules per BSA for immunization or immunoassay development. The final conjugate is lyophilized from PBS containing sugar-based stabilizer for easy shipment and storage.

The product is sold as either 1 vial of 1 mg (Cat# CM52140-1MG) or 5 vials of 1 mg (Cat# CM52140-5MG). For bulk orders, please contact us for a quote.

Key Features
• Lyophilized powder and ready for usage after reconstitution with water, no need for external buffer.
• Optimized loading with an average 3 to 5 Deruxtecan molecules per BSA
• Amount accurately determined by UV/HPLC analysis.

Please contact us at for specific academic pricing.